| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $7.68B | +3.8% |
| Cost of Revenue | $2.19B | +5.2% |
| R&D Expense | $437.4M | -4.6% |
| SG&A Expense | $2.93B | +3.2% |
| Operating Income | $1.29B | +0.6% |
| Pre-tax Income | $1.04B | -2.9% |
| Income Tax | $131.4M | +211.4% |
| Net Income | $903.8M | -11.7% |
| EPS (Basic) | $4.45 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $525.5M | +26.4% |
| Accounts Receivable | $1.48B | +2.7% |
| Inventory | $2.24B | -6.3% |
| Current Assets | $4.67B | +1.3% |
| Total Assets | $21.37B | -0.6% |
| Current Liabilities | $2.45B | -14.2% |
| Long-term Debt | $1.00B | -79.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Capital Expenditures | $203.8M | -30.0% |
| -9.4% |
| EPS (Diluted) | $4.43 | -9.2% |
| Total Liabilities |
| $8.89B |
| -1.3% |
| Stockholders' Equity | $12.47B | -0.1% |